Skip to main content

Table 2 Clinical characteristics of patients between the low and high SMI/SII groups

From: Skeletal muscle index/systemic immune-inflammation index (SMI/SII) ratio predicts prognosis in patients with hepatocellular carcinoma

Characteristics

Training (n = 728)

Validation-1 (n = 262)

Validation-2 (n = 404)

Combined cohorts (n = 1394)

Low (n = 365)

High (n = 363)

P

Low (n = 123)

High (n = 139)

P

Low (n = 157)

High (n = 247)

P

Low (n = 645)

High (n = 749)

P

Age (years)*

53.3±12.1

52.8±11.3

0.622

53.5±13.3

55.4±13.5

0.241

54.4±11.9

56.8±11.1

0.039

53.6±12.3

54.6±11.8

0.105

Sex

  

0.050

  

0.050

  

0.778

  

0.596

 Male

302 (82.7)

319 (87.9)

 

107 (87.0)

108 (77.7)

 

140 (89.2)

218 (88.3)

 

549 (85.1)

645 (86.1)

 

 Female

63 (17.3)

44 (12.1)

 

16 (13.0)

31 (22.3)

 

17 (10.8)

29 (11.7)

 

96 (14.9)

104 (13.9)

 

BMI (kg/m2) #

21.9 (19.8–24.3)

22.9 (20.8–25.5)

< 0.001

22.5 (20.2–25.8)

22.9 (19.9–25.8)

0.976

22.0 (19.6–24.7)

22.7 (20.8–25.5)

0.010

21.0 (18.0-23.7)

21.9 (18.6–24.8)

< 0.001

BCLC staging (n, %)

  

< 0.001

  

0.776

  

-

  

< 0.001

 0

12 (3.3)

39 (10.7)

 

10 (8.1)

10 (7.2)

 

0

0

 

22 (3.4)

49 (6.5)

 

 A

353 (96.7)

324 (89.3)

 

113 (91.9)

129 (92.8)

 

0

0

 

466 (72.2)

453 (60.5)

 

 B

-

-

 

-

-

 

157

247

 

157 (24.3)

247 (33.0)

 

Etiologies of hepatitis (n, %)

  

0.034

  

0.646

  

0.032

  

0.006

 None

48 (13.2)

29 (8.0)

 

34 (27.6)

33 (23.7)

 

29 (18.5)

25 (10.1)

 

111 (17.2)

87 (11.6)

 

 HBV

266 (72.9)

292 (80.4)

 

85 (69.1)

103 (74.1)

 

121 (77.1)

203 (82.2)

 

472 (73.2)

598 (79.8)

 

 Others

51 (14.0)

42 (11.6)

 

4 (3.3)

3 (2.2)

 

7 (4.5)

19 (7.7)

 

62 (9.6)

64 (8.5)

 

Liver cirrhosis (n, %)

  

< 0.001

  

< 0.001

  

< 0.001

  

< 0.001

 Absence

200 (54.8)

154 (42.4)

 

38 (30.9)

88 (63.3)

 

90 (57.3)

63 (25.5)

 

328 (50.9)

305 (40.7)

 

 Presence

165 (45.2)

209 (57.6)

 

85 (69.1)

51 (36.7)

 

67 (42.7)

184 (74.5)

 

317 (49.1)

444 (59.3)

 

Tumor size (n, %)

  

< 0.001

  

0.909

  

< 0.001

  

< 0.001

 ≤ 50 mm

108 (29.6)

243 (66.9)

 

69 (56.1)

77 (55.4)

 

37 (23.6)

174 (70.4)

 

214 (33.2)

494 (66.0)

 

 > 50 mm

257 (70.4)

120 (33.1)

 

54 (43.9)

62 (44.6)

 

120 (76.4)

73 (29.6)

 

431 (66.8)

255 (34.0)

 

Number of tumors (n, %)

  

0.893

  

0.955

  

-

  

0.005

 Solitary

310 (84.9)

307 (84.6)

 

105 (85.4)

119 (85.6)

 

0

0

 

415 (64.3)

426 (56.9)

 

 Multinodular

55 (15.1)

56 (15.4)

 

18 (14.6)

20 (14.4)

 

157

247

 

230 (35.7)

323 (43.1)

 

Up-to-seven criteria (n, %)

  

< 0.001

  

0.632

  

< 0.001

  

< 0.001

 Within

142 (38.9)

276 (76.0)

 

77 (62.6)

83 (59.7)

 

33 (21.0)

163 (66.0)

 

252 (39.1)

522 (69.7)

 

 Beyond

223 (61.1)

87 (24.0)

 

46 (37.4)

56 (40.3)

 

124 (79.0)

84 (34.0)

 

393 (60.9)

227 (30.3)

 

Creatine (umol/L) #

70.2 (59.6–79.6)

72.2 (63.0-83.5)

0.006

66.0 (59.0-79.7)

66.0 (55.4–75.8)

0.110

71.8 (61.9–79.3)

72.7 (62.0-81.9)

0.582

70.1 (60.0-79.3)

71.2 (61.0–81.0)

0.098

Total bilirubin (umol/L) #

13.0 (9.3–17.6)

14.6 (11.0-19.2)

< 0.001

14.4 (10.5–20.2)

11.6 (8.7–17.1)

0.004

14.7 (11.4–21.0)

16.5 (12.6–24.2)

0.045

13.7 (10.1–19.1)

14.8 (11.0–20.0)

0.007

Albumin (g/L) #

38.6 (35.6–41.4)

38.7 (36.1–41.1)

0.662

41.5 (37.5–44.6)

40.9 (37.1–43.5)

0.126

38.3 (35.2–41.2)

37.5 (33.2–41.0)

0.148

39.0 (35.7–42.1)

38.7 (35.6–41.6)

0.197

ALBI grade (n, %)

  

0.698

  

0.845

  

0.698

  

0.508

 I

156 (42.7)

150 (41.3)

 

80 (65.0)

92 (66.2)

 

57 (36.3)

85 (34.4)

 

293 (45.4)

327 (43.7)

 

 II

209 (57.3)

213 (58.7)

 

43 (35.0)

47 (33.8)

 

100 (63.7)

162 (65.6)

 

352 (54.6)

422 (56.3)

 

Neutrophil (× 109) #

4.33 (3.40–5.35)

2.64 (2.04–3.38)

< 0.001

3.51 (2.26–4.55)

3.05 (2.18–3.94)

0.103

4.36 (3.30–5.53)

2.29 (1.71–3.01)

< 0.001

4.20 (3.18–5.24)

2.60 (1.90–3.36)

< 0.001

Lymphocyte (× 109) #

1.32 (1.03–1.63)

1.41 (1.06–1.84)

0.019

1.25 (0.97–1.77)

1.37 (1.05–1.86)

0.161

1.21 (0.90–1.61)

1.27 (0.92–1.70)

0.575

1.30 (1.01–1.66)

1.36 (1.02–1.80)

0.026

Platelet (× 109) #

210.0 (163.0-258.5)

122.0 (86.0-159.0)

< 0.001

157.0 (101.0-215.0)

147.0 (101.0-209.0)

0.924

199.0 (154.5-250.5)

99.0 (68.0-136.0)

< 0.001

196.5 (148.9-251.1)

118.2 (81.0-159.1)

< 0.001

Monocyte (× 109) #

0.38 (0.27–0.51)

0.28 (0.21–0.37)

< 0.001

0.43 (0.34–0.57)

0.46 (0.34–0.62)

0.294

0.48 (0.36–0.62)

0.33 (0.23–0.46)

< 0.001

0.41 (0.29–0.54)

0.32 (0.23–0.44)

< 0.001

SII #

623.6 (469.2-915.1)

236.9 (154.8-307.6)

< 0.001

592.3 (446.8-840.7)

203.3 (146.8-284.8)

< 0.001

659.9 (479.7-1029.5)

190.7 (120.7-252.7)

< 0.001

628.1 (466.1-931.5)

209.6 (141.0-289.0)

< 0.001

SMA (cm2) #

107.9 (88.5–124.0)

119.9 (104.3-137.2)

< 0.001

109.3 (82.9-124.8)

118.1 (102.1-137.6)

< 0.001

109.1 (85.8-125.7)

118.6 (102.3-136.6)

< 0.001

108.3 (86.2-124.7)

119.2 (103.8-136.9)

< 0.001

SMI (cm2/m2) #

38.9 (32.7–44.2)

43.6 (38.0-49.2)

< 0.001

39.2 (30.6–45.1)

43.6 (37.4–49.7)

< 0.001

40.4 (32.5–44.9)

43.2 (37.3–49.0)

< 0.001

39.1 (32.4–44.4)

43.5 (37.5–49.1)

< 0.001

AFP level (n, %)

  

0.011

  

0.121

  

< 0.001

  

< 0.001

≤ 200ng/mL

207 (56.7)

239 (65.8)

 

69 (56.1)

91 (65.5)

 

72 (45.9)

162 (65.6)

 

348 (54.0)

492 (65.7)

 

> 200ng/mL

158 (43.3)

124 (34.2)

 

54 (43.9)

48 (34.5)

 

85 (54.1)

85 (34.4)

 

297 (46.0)

257 (34.3)

 
  1. Note: *, data are presented as mean ± SD; #, data are presented as median and IQR
  2. Abbreviations: SMI/SII, SMI to SII ratio; BMI, body mass index; BCLC, Barcelona clinic liver cancer; HBV, hepatitis B virus; ALBI, albumin-bilirubin; SII, systemic immune-inflammation index; SMA, skeletal muscle area; SMI, skeletal muscle index; AFP, alpha-fetoprotein